Beren pockets $300m to take Niemann-Pick disease therapy to market

Thursday, June 11, 2026Annabel Kartal AllenView original

If approved, Beren's adrabetadex would join Zevra Therapeutics’ Miplyffa and IntraBio’s Aqneursa on the I-NPC market.

Read the full article on the original site.